Cargando…
Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic
The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 2(4) factorial designs. Under optimized conditions, t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966939/ https://www.ncbi.nlm.nih.gov/pubmed/36839834 http://dx.doi.org/10.3390/pharmaceutics15020512 |
_version_ | 1784897141225816064 |
---|---|
author | Damasceno Junior, Elmar Barbosa, Raquel de Melo da Silva, Rita de Cássia Dantas Costa, Felipe dos Santos da Silva, Djalma Ribeiro Viseras, César Perioli, Luana Fernandes, Nedja Suely |
author_facet | Damasceno Junior, Elmar Barbosa, Raquel de Melo da Silva, Rita de Cássia Dantas Costa, Felipe dos Santos da Silva, Djalma Ribeiro Viseras, César Perioli, Luana Fernandes, Nedja Suely |
author_sort | Damasceno Junior, Elmar |
collection | PubMed |
description | The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 2(4) factorial designs. Under optimized conditions, the experiment allowed an incorporated drug dose equivalent to 98.60 ± 1.21 mg/g. Hybrid systems were characterized by different characterization techniques (FTIR, XRD, TGA, DSC, and SEM) to elucidate the mechanism of interaction between the compounds used. Through in vitro release studies, it was possible to verify the efficacy of the pH-dependent system obtained, with approximately 70% of the drug released after sixteen hours in simulated intestinal fluid. The adjustment of the experimental release data to the theoretical model of Higuchi and Korsmeyer–Peppas indicated that the release of rifampicin occurs in a prolonged form from montmorillonite. Elucidation of the interactions between the drug and this raw clay reinforces its viability as a novel carrier to develop an anti-TB/clay hybrid system with good physical and chemical stability. |
format | Online Article Text |
id | pubmed-9966939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99669392023-02-26 Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic Damasceno Junior, Elmar Barbosa, Raquel de Melo da Silva, Rita de Cássia Dantas Costa, Felipe dos Santos da Silva, Djalma Ribeiro Viseras, César Perioli, Luana Fernandes, Nedja Suely Pharmaceutics Article The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 2(4) factorial designs. Under optimized conditions, the experiment allowed an incorporated drug dose equivalent to 98.60 ± 1.21 mg/g. Hybrid systems were characterized by different characterization techniques (FTIR, XRD, TGA, DSC, and SEM) to elucidate the mechanism of interaction between the compounds used. Through in vitro release studies, it was possible to verify the efficacy of the pH-dependent system obtained, with approximately 70% of the drug released after sixteen hours in simulated intestinal fluid. The adjustment of the experimental release data to the theoretical model of Higuchi and Korsmeyer–Peppas indicated that the release of rifampicin occurs in a prolonged form from montmorillonite. Elucidation of the interactions between the drug and this raw clay reinforces its viability as a novel carrier to develop an anti-TB/clay hybrid system with good physical and chemical stability. MDPI 2023-02-03 /pmc/articles/PMC9966939/ /pubmed/36839834 http://dx.doi.org/10.3390/pharmaceutics15020512 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Damasceno Junior, Elmar Barbosa, Raquel de Melo da Silva, Rita de Cássia Dantas Costa, Felipe dos Santos da Silva, Djalma Ribeiro Viseras, César Perioli, Luana Fernandes, Nedja Suely Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic |
title | Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic |
title_full | Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic |
title_fullStr | Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic |
title_full_unstemmed | Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic |
title_short | Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic |
title_sort | montmorillonite–rifampicin nanohybrid for ph-responsive release of the tuberculostatic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966939/ https://www.ncbi.nlm.nih.gov/pubmed/36839834 http://dx.doi.org/10.3390/pharmaceutics15020512 |
work_keys_str_mv | AT damascenojuniorelmar montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic AT barbosaraqueldemelo montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic AT dasilvaritadecassiadantas montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic AT costafelipedossantos montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic AT dasilvadjalmaribeiro montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic AT viserascesar montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic AT perioliluana montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic AT fernandesnedjasuely montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic |